Insider transactions

EDGAR

BIO-RAD LABORATORIES, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
4 transactions, 3,771 shares
Sum of shares × price per share: 1,382,636.16

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 103

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-10 Filed 2026-11-12ENLOE COURTNEY C Officer: EVP, General Counsel Sec
S

Open market or private sale of non-derivative or derivative security

Bio-Rad A Common Stock
Disposed (D)902386.165
348,320.83

Derived: shares × price per share. Exact value 348320.830.

749.777Direct (D) No— Open filing 0000012208-26-000062 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12DiVincenzo Jonathan P. Officer: President COO
S

Open market or private sale of non-derivative or derivative security

Bio-Rad A Common Stock
Disposed (D)919390.47
358,841.93

Derived: shares × price per share. Exact value 358841.93.

1,962Direct (D) No— Open filing 0001453524-26-000005 Read from the filing’s XML Dispute this row
2026-11-09 Filed 2026-11-12BARRY JAMES Officer: EVP, President, LSG
S

Open market or private sale of non-derivative or derivative security

Bio-Rad A Common Stock
Disposed (D)1,400385.626
539,876.4

Derived: shares × price per share. Exact value 539876.400.

624.682Direct (D) No
F1
  • F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $385.588 to $385.645, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0000012208-26-000060 Read from the filing’s XML Dispute this row
2026-10-24 Filed 2026-10-27DiVincenzo Jonathan P. Officer: President COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)1,8690—3,832Direct (D) No
F1
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
Open filing 0000012208-26-000050 Read from the filing’s XML Dispute this row
2026-10-24 Filed 2026-10-27DiVincenzo Jonathan P. Officer: President COO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)951369.95
351,822.45

Derived: shares × price per share. Exact value 351822.45.

2,881Direct (D) No— Open filing 0000012208-26-000050 Read from the filing’s XML Dispute this row
2026-10-24 Filed 2026-10-27DiVincenzo Jonathan P. Officer: President COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (1,869) — exercise price 0
Disposed (D)1,8690—3,740Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F3 The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Open filing 0000012208-26-000050 Read from the filing’s XML Dispute this row
2026-10-20 Filed 2026-10-22EVRAN SEDAT Officer: EVP, Global Supply Chain
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)1,0440—4,647.12Direct (D) No
F1
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
Open filing 0001993147-26-000004 Read from the filing’s XML Dispute this row
2026-10-20 Filed 2026-10-22EVRAN SEDAT Officer: EVP, Global Supply Chain
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)487354.50
172,641.5

Derived: shares × price per share. Exact value 172641.50.

4,160.12Direct (D) No— Open filing 0001993147-26-000004 Read from the filing’s XML Dispute this row
2026-10-20 Filed 2026-10-22EVRAN SEDAT Officer: EVP, Global Supply Chain
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (1,044) — exercise price 0
Disposed (D)1,0440—1,044Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F3 On October 20, 2023, the reporting person was granted 4,176 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
Open filing 0001993147-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09Lakkaraju Roop Kalyan Officer: EVP, Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)1,5360—4,932.963Direct (D) No
F1
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
Open filing 0001396867-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09Lakkaraju Roop Kalyan Officer: EVP, Chief Financial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)782386.11
301,938.02

Derived: shares × price per share. Exact value 301938.02.

4,150.963Direct (D) No— Open filing 0001396867-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09Lakkaraju Roop Kalyan Officer: EVP, Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (1,536) — exercise price 0
Disposed (D)1,5360—3,072Direct (D) No
F3, F5
  • F3 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F5 The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Open filing 0001396867-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09SCHWARTZ NORMAN D Director · Officer: Chairman CEO · 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)3,4550—450,873Direct (D) No
F1
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
Open filing 0000940805-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09SCHWARTZ NORMAN D Director · Officer: Chairman CEO · 10% owner
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)1,854386.11
715,847.94

Derived: shares × price per share. Exact value 715847.94.

449,019Direct (D) No— Open filing 0000940805-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09SCHWARTZ NORMAN D Director · Officer: Chairman CEO · 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (3,455) — exercise price 0
Disposed (D)3,4550—6,912Direct (D) No
F5, F7
  • F5 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F7 The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Open filing 0000940805-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09EVRAN SEDAT Officer: EVP, Global Supply Chain
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)8640—3,880.12Direct (D) No
F1
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
Open filing 0001993147-26-000002 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09EVRAN SEDAT Officer: EVP, Global Supply Chain
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)277386.11
106,952.47

Derived: shares × price per share. Exact value 106952.47.

3,603.12Direct (D) No— Open filing 0001993147-26-000002 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09EVRAN SEDAT Officer: EVP, Global Supply Chain
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (864) — exercise price 0
Disposed (D)8640—1,728Direct (D) No
F3, F5
  • F3 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F5 The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Open filing 0001993147-26-000002 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09Allison Schwartz Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)920—1,768Direct (D) No
F1
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
Open filing 0001924980-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09Allison Schwartz Director
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)34386.11
13,127.74

Derived: shares × price per share. Exact value 13127.74.

1,734Direct (D) No— Open filing 0001924980-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09Allison Schwartz Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (92) — exercise price 0
Disposed (D)920—185Direct (D) No
F2, F4
  • F2 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F4 The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Open filing 0001924980-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09ENGELHARDT EVA ANETTE Officer: EVP, President, CDG
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)1,1520—2,313Direct (D) No
F1
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
Open filing 0002024911-26-000006 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09ENGELHARDT EVA ANETTE Officer: EVP, President, CDG
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)485386.11
187,263.35

Derived: shares × price per share. Exact value 187263.35.

1,828Direct (D) No— Open filing 0002024911-26-000006 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09ENGELHARDT EVA ANETTE Officer: EVP, President, CDG
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (1,152) — exercise price 0
Disposed (D)1,1520—2,304Direct (D) No
F2, F4
  • F2 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F4 The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Open filing 0002024911-26-000006 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09ENLOE COURTNEY C Officer: EVP, General Counsel Sec
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)7680—1,956.777Direct (D) No
F1
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
Open filing 0002019843-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09ENLOE COURTNEY C Officer: EVP, General Counsel Sec
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)305386.11
117,763.55

Derived: shares × price per share. Exact value 117763.55.

1,651.777Direct (D) No— Open filing 0002019843-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09ENLOE COURTNEY C Officer: EVP, General Counsel Sec
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (768) — exercise price 0
Disposed (D)7680—1,536Direct (D) No
F2, F4
  • F2 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F4 The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Open filing 0002019843-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09BARRY JAMES Officer: EVP, President, LSG
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)1,0560—2,494.682Direct (D) No
F1
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
Open filing 0002022345-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09BARRY JAMES Officer: EVP, President, LSG
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)470386.11
181,471.7

Derived: shares × price per share. Exact value 181471.70.

2,024.682Direct (D) No— Open filing 0002022345-26-000004 Read from the filing’s XML Dispute this row
2026-09-06 Filed 2026-09-09BARRY JAMES Officer: EVP, President, LSG
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (1,056) — exercise price 0
Disposed (D)1,0560—2,112Direct (D) No
F2, F4
  • F2 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F4 The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Open filing 0002022345-26-000004 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09DiVincenzo Jonathan P. Officer: President COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)1,7120—2,631Direct (D) No
F1
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
Open filing 0001453524-26-000002 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09DiVincenzo Jonathan P. Officer: President COO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)668386.11
257,921.48

Derived: shares × price per share. Exact value 257921.48.

1,963Direct (D) No— Open filing 0001453524-26-000002 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09DiVincenzo Jonathan P. Officer: President COO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (1,712) — exercise price 0
Disposed (D)1,7120—5,138Direct (D) No
F2, F4
  • F2 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F4 The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Open filing 0001453524-26-000002 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09Lakkaraju Roop Kalyan Officer: EVP, Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)1,3700—3,955.963Direct (D) No
F1, F2
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
  • F2 Includes 22.0680 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2026.
Open filing 0001396867-26-000004 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09Lakkaraju Roop Kalyan Officer: EVP, Chief Financial Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)559386.11
215,835.49

Derived: shares × price per share. Exact value 215835.49.

3,396.963Direct (D) No— Open filing 0001396867-26-000004 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09Lakkaraju Roop Kalyan Officer: EVP, Chief Financial Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (1,370) — exercise price 0
Disposed (D)1,3700—4,110Direct (D) No
F3, F5
  • F3 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F5 The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Open filing 0001396867-26-000004 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09SCHWARTZ NORMAN D Director · Officer: Chairman CEO · 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)4,1090—450,294Direct (D) No
F1
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
Open filing 0000940805-26-000004 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09SCHWARTZ NORMAN D Director · Officer: Chairman CEO · 10% owner
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)2,876386.11
1,110,452.36

Derived: shares × price per share. Exact value 1110452.36.

447,418Direct (D) No— Open filing 0000940805-26-000004 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09SCHWARTZ NORMAN D Director · Officer: Chairman CEO · 10% owner
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (4,109) — exercise price 0
Disposed (D)4,1090—12,330Direct (D) No
F5, F7
  • F5 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F7 The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Open filing 0000940805-26-000004 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09EVRAN SEDAT Officer: EVP, Global Supply Chain
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)1,0270—3,345.12Direct (D) No
F1, F2
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
  • F2 Includes 51.2870 and 33.9860 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 03/31/2026 and 06/30/2026, respectively.
Open filing 0001993147-26-000002 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09EVRAN SEDAT Officer: EVP, Global Supply Chain
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)329386.11
127,030.19

Derived: shares × price per share. Exact value 127030.19.

3,016.12Direct (D) No— Open filing 0001993147-26-000002 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09EVRAN SEDAT Officer: EVP, Global Supply Chain
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (1,027) — exercise price 0
Disposed (D)1,0270—3,083Direct (D) No
F3, F5
  • F3 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F5 The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Open filing 0001993147-26-000002 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09Allison Schwartz Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)2280—1,758Direct (D) No
F1
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
Open filing 0001924980-26-000004 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09Allison Schwartz Director
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)82386.11
31,661.02

Derived: shares × price per share. Exact value 31661.02.

1,676Direct (D) No— Open filing 0001924980-26-000004 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09Allison Schwartz Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (228) — exercise price 0
Disposed (D)2280—686Direct (D) No
F2, F4
  • F2 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F4 The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Open filing 0001924980-26-000004 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09Mehta Rajat Officer: EVP, GBL Commercial Operations
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)4560—599.052Direct (D) No
F1, F2
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
  • F2 Includes 57.9370, 53.0810 and 32.0340 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 12/31/2025, 03/31/2026 and 06/30/2026, respectively.
Open filing 0002081681-26-000002 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09Mehta Rajat Officer: EVP, GBL Commercial Operations
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)233386.11
89,963.63

Derived: shares × price per share. Exact value 89963.63.

366.052Direct (D) No— Open filing 0002081681-26-000002 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09Mehta Rajat Officer: EVP, GBL Commercial Operations
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Bio-Rad A Common Stock
Acquired (A)1,3700—1,736.052Direct (D) No
F1
  • F1 Shares of Class A common stock acquired on the vesting of restricted stock units.
Open filing 0002081681-26-000002 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09Mehta Rajat Officer: EVP, GBL Commercial Operations
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Bio-Rad A Common Stock
Disposed (D)504386.11
194,599.44

Derived: shares × price per share. Exact value 194599.44.

1,232.052Direct (D) No— Open filing 0002081681-26-000002 Read from the filing’s XML Dispute this row
2026-09-05 Filed 2026-09-09Mehta Rajat Officer: EVP, GBL Commercial Operations
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Bio-Rad A Common Stock (456) — exercise price 0
Disposed (D)4560—1,371Direct (D) No
F3, F5
  • F3 Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
  • F5 The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Open filing 0002081681-26-000002 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,905 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,170 filings read.

Showing 1–7 of 7

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Focus Partners Wealth 760 SH286,170 dollarsNot in the prior quarter’s filings read Open filing 0001542153-26-000021 Filed 2026-11-12 Dispute this row
MORGAN STANLEY Partly reported under another manager627 SH236,091 dollarsLower by 85 Prior quarter: 712Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
WELLS FARGO COMPANY/MN Partly reported under another manager170 SH62,064 dollarsUnchanged Prior quarter: 170Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row
WHITTIER TRUST CO 160 SH58,054 dollarsUnchanged Prior quarter: 160Open filing 0001999371-26-025126 Filed 2026-11-12 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager146 SH54,910 dollarsNot in the prior quarter’s filings read Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row
SIMPLEX TRADING, LLC Option: Call 100 SH37,771 dollarsNot in the prior quarter’s filings read Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row
UBS Group AG Partly reported under another manager90 SH33,889 dollarsHigher by 77 Prior quarter: 13Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • FLOW TRADERS U.S. LLC 760 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

Showing 1–12 of 12

House members’ trades in this company, newest report first, as filed
MemberTransaction dateTypeAmountOwnerReport
Hon. Lois Frankel (FL22)2023-09-08Sale$1,001 - $15,0002023-10-10
Hon. Lois Frankel (FL22)2023-06-29Purchase$1,001 - $15,0002023-07-28
Hon. Lois Frankel (FL22)2023-06-28Purchase$1,001 - $15,0002023-07-28
Hon. Susie Lee (NV03)2022-11-30Sale$1,001 - $15,000JT2022-12-29
Hon. Susie Lee (NV03)2021-01-05Sale (partial)$1,001 - $15,000JT2021-02-10
Hon. Susie Lee (NV03)2020-10-02Sale (partial)$1,001 - $15,000JT2020-12-08
Hon. Susie Lee (NV03)2020-05-27Sale (partial)$1,001 - $15,000JT2020-06-15
Hon. Susie Lee (NV03)2020-04-07Sale (partial)$1,001 - $15,000JT2020-06-15
Hon. Susie Lee (NV03)2019-12-27Sale (partial)$1,001 - $15,000JT2020-01-16
Hon. Susie Lee (NV03)2019-06-25Purchase$1,001 - $15,000JT2019-07-18
Hon. Susie Lee (NV03)2019-04-25Purchase$1,001 - $15,000JT2019-05-09
Hon. Thomas MacArthur (NJ03)2015-05-27Sale$1,001 - $15,000JT2015-06-07

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 13Open filing 0000102909-26-000749 Dispute this row
BlackRock, Inc. Class A Stock7.41,618,12309/30/2025 Filed 2025-10-17SCHEDULE 13G/AAmendment 12Open filing 0002012383-25-002837 Dispute this row
Norman D. Schwartz Class B Common Stock97.24,929,036.0009/25/2025 Filed 2025-10-30SCHEDULE 13D/AAmendment 9Open filing 0000940805-25-000007 Dispute this row
Steven D. Schwartz Class B Common Stock80.84,098,294.0009/25/2025 Filed 2025-10-30SCHEDULE 13D/AAmendment 9Open filing 0000940805-25-000007 Dispute this row
Blue Raven Partners, L.P. Class B Common Stock80.14,060,054.0009/25/2025 Filed 2025-10-30SCHEDULE 13D/AAmendment 9Open filing 0000940805-25-000007 Dispute this row
Alice N. Schwartz Revocable Trust Class B Common Stock8.6437,510.0009/25/2025 Filed 2025-10-30SCHEDULE 13D/AAmendment 9Open filing 0000940805-25-000007 Dispute this row
Norman D. Schwartz Class A Common Stock14.63,228,922.0009/25/2025 Filed 2025-10-30SCHEDULE 13D/AAmendment 7Open filing 0000012208-25-000083 Dispute this row
Alice N. Schwartz Revocable Trust Class A Common Stock8.11,781,356.0009/25/2025 Filed 2025-10-30SCHEDULE 13D/AAmendment 7Open filing 0000012208-25-000083 Dispute this row
Norman D. Schwartz Class A Common Stock14.63,228,922.0009/25/2025 Filed 2025-10-28SCHEDULE 13D/AAmendment 7Open filing 0000012208-25-000069 Dispute this row
Alice N. Schwartz Revocable Trust Class A Common Stock8.11,781,356.0009/25/2025 Filed 2025-10-28SCHEDULE 13D/AAmendment 7Open filing 0000012208-25-000069 Dispute this row
Norman D. Schwartz Class B Common Stock97.24,929,036.0009/25/2025 Filed 2025-10-28SCHEDULE 13D/AAmendment 9Open filing 0000012208-25-000070 Dispute this row
Steven D. Schwartz Class B Common Stock80.84,098,294.0009/25/2025 Filed 2025-10-28SCHEDULE 13D/AAmendment 9Open filing 0000012208-25-000070 Dispute this row
Blue Raven Partners, L.P. Class B Common Stock80.14,060,054.0009/25/2025 Filed 2025-10-28SCHEDULE 13D/AAmendment 9Open filing 0000012208-25-000070 Dispute this row
Alice N. Schwartz Revocable Trust Class B Common Stock8.6437,510.0009/25/2025 Filed 2025-10-28SCHEDULE 13D/AAmendment 9Open filing 0000012208-25-000070 Dispute this row
First Eagle Investment Management, LLC Common11.42,528,321.4306/30/2025 Filed 2025-08-06SCHEDULE 13G/AAmendment 2Open filing 0001325447-25-000032 Dispute this row
FIRST EAGLE GLOBAL FUND Common8.51,878,739.0006/30/2025 Filed 2025-08-06SCHEDULE 13G/AAmendment 2Open filing 0001325447-25-000032 Dispute this row
Alice N. Schwartz Class A Common Stock12.32,732,073.0005/01/2025 Filed 2025-07-18SCHEDULE 13D/AAmendment 6Open filing 0000012208-25-000043 Dispute this row
Alice N. Schwartz Revocable Trust Class A Common Stock8.01,781,356.0005/01/2025 Filed 2025-07-18SCHEDULE 13D/AAmendment 6Open filing 0000012208-25-000043 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,584,041 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201517,857
2016222,642
2017222,009
2018223,345
2019216,482
2020210,332
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026262,405

Filings made before the SEC required XML are listed, not extracted.

Back to BIO-RAD LABORATORIES, INC.